Iniparib: Preliminary Phase II data

Preliminary data from 19 evaluable patients in a single-arm, open-label, U.S. Phase II trial showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 31.6%, with a median PFS of 5.9 months. The trial plans to enroll 48 patients with epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal carcinoma. Patients are receiving gemcitabine and carboplatin on days 1 and 8 of each 21-day cycle, plus 5.6 mg/kg BSI-201 on days 1, 4, 8 and 11 of each cycle. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...